Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 3.9% - Should You Sell?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report)'s stock price was down 3.9% on Thursday . The stock traded as low as $37.51 and last traded at $37.51. Approximately 81,594 shares traded hands during trading, a decline of 89% from the average daily volume of 719,378 shares. The stock had previously closed at $39.02.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Leerink Partners downgraded shares of Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $60.00 to $56.00 in a research report on Friday, September 27th. Royal Bank of Canada raised their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a report on Tuesday, December 10th. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a report on Wednesday. StockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, November 9th. Finally, Scotiabank lifted their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research report on Monday, December 9th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $56.33.

Agios Pharmaceuticals Stock Performance

The stock's fifty day moving average price is $49.94 and its 200-day moving average price is $46.71. The firm has a market cap of $2.04 billion, a PE ratio of 3.15 and a beta of 0.80.

Insider Buying and Selling

In related news, CFO Cecilia Jones sold 2,542 shares of the company's stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. This represents a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.93% of the stock is currently owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Erste Asset Management GmbH purchased a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth $97,199,000. Marshall Wace LLP raised its holdings in shares of Agios Pharmaceuticals by 307.8% in the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company's stock worth $48,887,000 after purchasing an additional 855,739 shares during the period. Vestal Point Capital LP purchased a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth about $33,767,000. Frazier Life Sciences Management L.P. grew its holdings in shares of Agios Pharmaceuticals by 66.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company's stock worth $37,600,000 after purchasing an additional 348,808 shares during the period. Finally, Candriam S.C.A. acquired a new position in Agios Pharmaceuticals during the second quarter valued at approximately $13,922,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.